Related Experiment Video
Updated: Mar 25, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Current and emerging treatment options in the management of advanced ovarian cancer
Victor Rodriguez-Freixinos1, Helen J Mackay2, Katherine Karakasis1
1a Division of Medical Oncology and Hematology, Princess Margaret Hospital , University of Toronto , Toronto , Ontario , Canada.
Introduction:
Epithelial ovarian cancer is the most lethal gynecologic malignancy. Recent advances in understanding the biology and its molecular and histological diversity have led to mechanism based therapeutic strategies such as poly-ADP-ribose polymerase inhibitors (PARP) targeting homologous recombination deficient tumor cells and anti-angiogenic therapies. Clinical trial designs in ovarian cancer have to evolve to incorporate assessment of the genomic complexity and identify predictive biomarkers to improve precision of treatment and outcome.
Areas Covered:
This review summarizes present-day strategies used in the management of ovarian cancer and novel promising therapeutic approaches in development. The article is based on English peer-reviewed articles located on MEDLINE and related abstracts presented at major international meetings.
Expert Opinion:
Two types of molecular targeted therapies, anti-angiogenics and PARP inhibitors, have been shown to be active in randomized clinical trials and approved by regulatory agencies. Management of ovarian cancer is poised to change with the continued advancement of precision medicine that is founded upon improved understanding of disease biology; separation into histologically and molecularly defined subgroups; and the incorporation of this new knowledge into early phase drug development and novel clinical trial design.
Insights
Precision medicine advances ovarian cancer treatment. Targeted therapies like PARP inhibitors and anti-angiogenics are improving outcomes by targeting specific tumor biology and incorporating genomic complexity into clinical trial designs.
Area of Science:
- Gynecologic Oncology
- Molecular Oncology
- Clinical Trial Design
Background:
- Epithelial ovarian cancer is a highly lethal gynecologic malignancy.
- Understanding its molecular and histological diversity drives new therapeutic strategies.
- Mechanism-based therapies include PARP inhibitors and anti-angiogenics.
Purpose of the Study:
- To review current ovarian cancer management strategies.
- To summarize novel and promising therapeutic approaches.
- To highlight the evolution of clinical trial design in ovarian cancer.
Main Methods:
- Literature review of English peer-reviewed articles from MEDLINE.
- Inclusion of abstracts from major international oncology meetings.
- Synthesis of current and emerging treatment modalities.
Main Results:
- Poly-ADP-ribose polymerase (PARP) inhibitors and anti-angiogenic therapies show efficacy in clinical trials.
- These targeted therapies have received regulatory approval.
- Genomic complexity and predictive biomarkers are crucial for treatment selection.
Conclusions:
- Ovarian cancer management is shifting towards precision medicine.
- Improved understanding of disease biology is key.
- Histological and molecular subtyping, alongside novel trial designs, will enhance precision treatment and patient outcomes.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies